Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

INSIDE INFORMATION ANNOUNCEMENT
COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by TransThera Sciences (Nanjing), Inc. (藥捷安康(南京)科技股份有限公司) (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated (i) October 20, 2025 in relation to the proposed implementation of the H share full circulation by the Company; (ii) October 26, 2026 in relation to the issuance of the filing notice by the China Securities Regulatory Commission for the H share full circulation of the Company and (iii) November 1, 2026 in relation to the grant of listing approval by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") for the implementation of the H share full circulation (collectively, the "**Announcements**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that the conversion of 44,971,128 Unlisted Shares held by the 10 Participating Shareholders into H Shares was completed on November 19, 2026, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on November 20, 2026.

SHAREHOLDING STRUCTURE

The share capital structure of the Company as at the date of this announcement and immediately upon completion of the Conversion and the Listing is set out below:

Class of shares	**Immediately before completion of the Conversion and the Listing**		**Upon completion of the Conversion and the Listing**	
	Number of shares	*Approximate percentage %*	*Number of shares*	*Approximate percentage %*
H shares	313,347,673	76.69%	358,318,801	87.70%
Unlisted shares	95,230,960	23.31%	50,259,832	12.30%
Total	408,578,633	100.00%	408,578,633	100.00%

Note: The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, November 19, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Ms. Chui Hoi Yam, Mr. Feng Weibo and Mr. Li Shu Pai as independent non-executive directors.